Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FERRY: Toripalimab Maintenance Therapy in Locally Advanced HNSCC After MPR
NCT06208826Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2023
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Disease Free Survival up to 4 years. Started Sep 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06208826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208826.